Regulation of Prostacyclin in Pulmonary Hypertension

前列环素在肺动脉高压中的调节

• 批准号: 7480211
• 负责人: SERGE PATRICK NANASINKAM
• 金额: $ 13.15万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-15 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7480211
• 关键词: Abbreviations; Admission activity; Affect; Animal Model; Biology; Blood Vessels; Chronic; Colorado; Critical Care; Development; Disease; Disease model; Disease susceptibility; Doctor of Medicine; Educational Activities; Effectiveness; Eicosanoids; Elements; Elevation; Endothelial Cells; Environment; Epoprostenol; Epoprostenol Receptors; Funding; Gene Expression; Genes; Genetic; Genetic Polymorphism; Genetic Transcription; Goals; Grant; Health Sciences; Human; Hypoxia; Individual; Infusion procedures; Knock-out; Knowledge; Laboratories; Lung; MAP Kinase Gene; Medicine; Mentored Clinical Scientist Award; Minisatellite Repeats; Minority; Mitogen-Activated Protein Kinases; Modeling; Molecular Biology Techniques; Mus; Pathway interactions; Platelet-Derived Growth Factor; Polymerase Chain Reaction; Population; Predisposition; Prevention; Promoter Regions; Property; Prostacyclin synthase; Prostaglandins I; Protein Overexpression; Pulmonary Hypertension; Pulmonary artery structure; Records; Regulation; Research; Research Design; Research Personnel; Role; Scholarship; Science; Signal Pathway; Smooth Muscle Myocytes; Systolic Pressure; Text; Time; Transcriptional Regulation; Transgenic Animals; Transgenic Organisms; United States National Institutes of Health; Universities; Vascular Endothelial Growth Factor Receptor; Vascular Endothelial Growth Factors; Vascular remodeling; Ventricular; Work; Writing; career; clinical application; cyclooxygenase 1; design; ethnic minority population; gene function; improved; instructor; interest; medical schools; parent grant; pressure; prevent; primary pulmonary hypertension; programs; promoter; response; skills; vasoconstriction

DESCRIPTION (provided by applicant): Candidate: The candidate, Patrick Nana-Sinkam, M.D., is an Instructor in the Division of Pulmonary Sciences and Critical Care Medicine at the University of Colorado Health Sciences Center. He is currently supported by an NIH minority supplement grant to the parent grant NIH E PATHO. PROJ IV 5P01 HL066254-03S1, "Prostacyclin Synthase and Prostacyclin Receptor in Severe Pulmonary Hypertension." Dr. Nana-Sinkam has previously worked on transgenic murine models of disease and has developed a particular interest in the eicosanoid pathway and its role in disease susceptibility as well as identifying products with clinical application. His short-term goal is to continue to develop both the professional and research skills to eventually become an independent investigator. Long term, Dr. Nana-Sinkam hopes to develop a successful, independently funded laboratory in eicosanoid biology. This proposed Mentored Clinical Scientist Award would provide him with the support to develop these skills. Career Development: Dr. Nana-Sinkam's career development will include: 1) developing new research skills such as the development of transgenic animal models, research design and professional skills necessary in an academic center, 2) formal educational activities including courses in molecular biology techniques and grant writing, and 3) involvement in administrative activities essential to developing professional skills such as serving on the School of Medicine's Admission and Scholarship Committees and Ethnic Minority Affairs Committee. Environment: Dr. Nana-Sinkam is currently in an environment that is conducive to excellent research. His sponsor, Dr. Mark Geraci, and co-sponsors, Drs. Norbert Voelkel and Raphael Nemenoff, are outstanding, extramurally funded, independent investigators with established records in research. Research: Dr. Nana-Sinkam's general goals will be to attempt to elucidate the mechanisms by which prostacyclin prevent vascular remodeling and are regulated in pulmonary hypertension. The hypotheses will be that 1) the development of a conditional transgenic murine model for overexpression of prostacyclin synthase can assist in defining the temporal relationship between gene expression and remodeling, 2) key regulators of gene transcription involved in suppression of prostacyclin in pulmonary hypertension can be identified by a model for gene transcriptional regulation, and 3) prostacyclin synthease gene polymorphisms exist in defined human populations and have a potential impact on gene function and subsequent susceptibility to disease.

描述(由申请人提供)： 候选人：帕特里克·纳纳-辛卡姆，医学博士，科罗拉多大学健康科学中心肺科学和重症监护医学部的讲师。他目前得到了NIH少数民族补充补助金的支持，父母赠款为NIH E PATEO。项目IV 5P01 HL066254-03S1，《重度肺动脉高压中的前列环素合成酶和前列环素受体》。Nana-Sinkam博士以前从事过转基因小鼠疾病模型的工作，并对二十烷类化合物途径及其在疾病易感性中的作用以及识别具有临床应用的产品产生了特别的兴趣。他的短期目标是继续发展专业和研究技能，最终成为一名独立的调查员。从长远来看，纳纳-辛卡姆博士希望在二十烷类生物学领域建立一个成功的、独立出资的实验室。这项拟议的临床科学家导师奖将为他提供发展这些技能的支持。 职业发展：Nana-Sinkam博士的职业发展将包括：1)发展新的研究技能，如开发转基因动物模型、研究设计和学术中心所需的专业技能；2)正规教育活动，包括分子生物学技术课程和拨款申请；3)参与发展专业技能所必需的行政活动，如在医学院招生和奖学金委员会以及少数民族事务委员会任职。 环境：Nana-Sinkam博士目前所处的环境有利于出色的研究。他的赞助人Mark Geraci博士和共同赞助人Norbert Voelkel博士和Raphael Nemenoff博士都是杰出的、由外部资助的独立调查人员，他们在研究方面有既定的记录。 研究：Nana-Sinkam博士的总体目标将是试图阐明前列环素防止血管重塑和调节肺动脉高压的机制。这些假设是：1)前列环素合成酶过表达的条件转基因小鼠模型的建立可以帮助确定基因表达和重塑之间的时间关系；2)参与抑制前列环素在肺动脉高压中作用的关键基因转录调节因子可以通过基因转录调控模型来识别；3)前列环素合成酶基因的多态性存在于特定的人群中，并对基因功能和随后的疾病易感性产生潜在的影响。

项目成果

MicroRNAs in the pathogenesis of Lung Cancer.

• DOI: 10.1097/jto.0b013e3181a99c77
• 发表时间: 2009-08
• 期刊: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
• 作者: Wu X;Piper-Hunter MG;Crawford M;Nuovo GJ;Marsh CB;Otterson GA;Nana-Sinkam SP
• 通讯作者: Nana-Sinkam SP

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.

• DOI: 10.1016/j.bbrc.2009.07.143
• 发表时间: 2009-10-23
• 期刊: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
• 影响因子: 3.1
• 作者: Crawford, Melissa;Batte, Kara;Yu, Lianbo;Wu, Xin;Nuovo, Gerard J.;Marsh, Clay B.;Otterson, Gregory A.;Nana-Sinkam, Serge P.
• 通讯作者: Nana-Sinkam, Serge P.